4-stilbazole: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 641098 |
| CHEMBL ID | 1566593 |
| SCHEMBL ID | 1878225 |
| SCHEMBL ID | 1509973 |
| MeSH ID | M0044384 |
| Synonym |
|---|
| LS-14186 |
| EN300-31340 |
| w9282v2uv3 , |
| 4-stilbazole, (e)- |
| 5097-93-8 |
| unii-w9282v2uv3 |
| 4-(2-phenylvinyl)pyridine, trans- |
| 4-(2-phenylethenyl)pyridine, (e) |
| nsc-44776 |
| nsc44776 |
| nsc-360203 |
| nsc360203 |
| smr000304935 |
| MLS000722940 |
| ba 35998 |
| 4-styrylpyridine |
| 103-31-1 |
| .gamma.-stilbazole |
| nsc9496 |
| nsc-9496 |
| ba 35988 |
| 4-(2-phenylvinyl)pyridine |
| 4-stilbazole |
| pyridine, 4-(2-phenylethenyl)- |
| pyridine, 4-styryl- |
| 4-[(e)-2-phenylvinyl]pyridine |
| pyridine, 4-[(e)-2-phenylethenyl]- |
| inchi=1/c13h11n/c1-2-4-12(5-3-1)6-7-13-8-10-14-11-9-13/h1-11h/b7-6 |
| SR-01000414340-2 |
| NCGC00160603-01 |
| AE-641/00643053 |
| NCGC00160603-02 |
| AKOS000279610 |
| HMS553B10 |
| 4-[(e)-2-phenylethenyl]pyridine |
| 4-(2-phenylethenyl)pyridine |
| cas-103-31-1 |
| tox21_111930 |
| tox21_113556 |
| dtxcid5026255 |
| SCHEMBL1878225 |
| STL262669 |
| ai3-09317 |
| einecs 203-099-0 |
| gamma-stilbazole |
| nsc 44776 |
| CCG-50412 |
| HMS2750O07 |
| MLS006011483 |
| smr004703267 |
| CHEMBL1566593 |
| (e)-4-styrylpyridine |
| (e)-4-(2-phenylethenyl)pyridine |
| SCHEMBL1509973 |
| Z276613790 |
| (e)-4-stilbazole |
| 4-trans-styrylpyridine |
| (e)-stilbazole |
| ba-35998 |
| pyridine, 4-(2-phenylethenyl)-, (e)- |
| pyridine, 4-((1e)-2-phenylethenyl)- |
| ba-35988 |
| pyridine, 4-styryl-, (e)- |
| 4-((1e)-2-phenylethenyl)pyridine |
| trans-4-styrylpyridine |
| trans-4-stilbazole |
| mfcd00137749 |
| F0722-3574 |
| sr-01000414340 |
| SR-01000414340-1 |
| 4-[(1e)-2-phenylethenyl]pyridine |
| F17039 |
| 4-((e)-styryl)-pyridine |
| AS-47936 |
| 4-(2-phenylethenyl)pyridine, e |
| Q27292487 |
| CS-0356737 |
| 39836-54-9 |
| CS-0215942 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.1995 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 29.5182 | 0.0072 | 15.7588 | 89.3584 | AID588342; AID624030 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 19.9526 | 3.9811 | 27.7649 | 39.8107 | AID504842 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 11.5774 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| AR protein | Homo sapiens (human) | Potency | 11.0237 | 0.0002 | 21.2231 | 8,912.5098 | AID743042; AID743054 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 15.1952 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079; AID743080; AID743091 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 1.9953 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 18.9976 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 21.1317 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 4.5479 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 13.3332 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 17.7828 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 21.9790 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 20.2478 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||